<DOC>
	<DOCNO>NCT00627744</DOCNO>
	<brief_summary>A three month , double-blind , randomise , parallel-group study evaluate efficacy sitagliptin ( Januvia™ ) versus placebo beta-cell function patient newly detect glucose abnormality acute myocardial infarction unstable angina pectoris . Primary endpoint Improvement beta-cell function measure mean insulinogenic index ( ΔI30/ΔG30 ) obtain oral glucose tolerance test ( OGTT ) . Secondary endpoint 1 . Improvement glucose tolerance mean OGTT 2 . Improvement endothelial function 3 . Improvement incretin-independent beta-cell function measure Acute Insulin Response ( ΔAIRG ) intravenous glucose tolerance test</brief_summary>
	<brief_title>Beta-cell Function Glucose Abnormalities Acute Myocardial Infarction</brief_title>
	<detailed_description>GENERAL AIM / PRIMARY OBJECTIVE The primary objective show sitagliptin ( Januvia™ ) 100 mg daily three month improve beta-cell function patient AMI unstable angina pectoris newly discover glucose abnormality ( IGT T2DM ) . PRIMARY ENDPOINT The primary endpoint improvement beta-cell function three month treatment measure mean insulinogenic index ( ΔI30/ΔG30 ) obtain oral glucose tolerance test ( OGTT ) . SECONDARY ENDPOINTS 1 . Improvement glucose tolerance test OGTT three month . 2 . Improvement endothelial function ( measure Endo-PAT2000 , Itamar ) three month . 3 . Improvement GLP-1 independent beta-cell function three month measure ΔAIRG obtain `` Frequently sample intravenous glucose tolerance test '' ( FSIGT ) . NUMBER OF PATIENTS PLANNED A total 70-80 consecutive patient include 35-40 patient treatment arm . TREATMENTS TO BE COMPARED Active substance : Sitagliptin Januvia™ 100 mg daily orally three month Comparator drug Placebo CONCOMITANT THERAPY All patient receive evidence base treatment secondary prevention coronary heart disease accord recent ESC guideline [ 60,61 ] . All patient receive structured life style intervention strategy accord local practise . EFFICACY The primary endpoint improvement beta-cell function three month treatment measure mean insulinogenic index ( ΔI30/ΔG30 ) obtain oral glucose tolerance test ( OGTT ) . Secondary endpoint 1 . Improvement glucose tolerance test OGTT three month . 2 . Improvement endothelial function ( measure Endo-PAT2000 , Itamar ) three month . 3 . Improvement GLP-1 independent beta-cell function three month measure ΔAIRG obtain `` Frequently sample intravenous glucose tolerance test '' ( FSIGT ) . Methodology OGTT : Oral administration 75 g Glucose 200 ml water lemon extract administer morning follow overnight fast 12 hour A capillary blood glucose curve obtain 2 hour ( 30 , 60 , 90 120 minute glucose ingestion ) . Endo-PAT2000 : The Endo-PAT2000 non-invasive device non-invasive characterisation endothelial function dysfunction arterial stiffness . The endothelial function assessment base endothelial mediate arterial response ( level distal phalanx finger ) five-minute occlusion brachial artery . FSIGT : The patient investigate morning overnight fast . A catheter insert antecubital vein blood sample contralateral antecubital vein glucose injection . Basal sample draw 10 1 min . At time 0 , glucose ( 300 mg/kg ) inject 1 min , additional sample collect 3 , 4 , 5 , 6 , 8 , 10 , 15 , 20 , 25 , 30 , 40 , 60 , 80 , 100 , 120 , 150 , 180 min [ 62 ] . INVESTIGATIONAL PLAN This three month , double-blind , randomise , parallel-group study evaluate efficacy sitagliptin ( Januvia™ ) versus placebo beta-cell function patient AMI unstable angina pectoris newly discover glucose abnormality ( IGT + T2DM ) . SAMPLE SIZE ISSUES The assumption sample size calculation base previous study group insulinogenic index measure patient AMI newly discover type 2 diabetes IGT [ 21 ] . The mean standard-deviation ΔAIRG estimate 50 ± 35 ( pmol/mmol ) . To detect increase 50 % two treatment group 5 % level significance 80 % power use two-tailed t-test , sample size 64 patient would necessary ( PROC POWER SAS 9.1.3 ) . With additional 5 % able use non-parametric method total sample size set 70 patient . ETHICS AND REGULATORY The trial initiate protocol inform consent subject information form review receive approval local ethic committee . Informed Consent Subject Information Each patient receive oral write information . Patients include follow oral write consent . Patient data protect patient insured Swedish law . All patient must inform , whenever wish , may withdraw study case withdrawal treat accord best possible routine standard centre . QUALITY ASSURANCE AUDIT Monitoring visit perform inclusion first subject , regularly trial conduct data base closed collaboration Karolinska Clinical Research Trial Support Centre . The investigator permit trial-related monitoring , audit , IRB/IEC review , regulatory inspection , provide direct access source data/documents . ADVERSE EVENTS All adverse event , serious non-serious , occur course clinical trial collect , document report sponsor investigator . An adverse event define untoward medical occurrence clinical investigation subject administer pharmaceutical product necessarily causal relationship treatment . The non-serious adverse event observe patient treat sitagliptin ( &gt; 5 % incidence great incidence placebo ) :</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Patients diagnose acute myocardial infarction unstable angina pectoris accord joint ESC ACC recommendation [ 58 ] . 2 . Classification impair glucose tolerance ( IGT ) type 2 diabetes ( T2DM ) mean oral glucose tolerance test ( OGTT ) accord WHO [ 59 ] . 3 . Patients sign write informed consent consistent ICHGCP guideline local legislation prior participation trial . Exclusion criterion : 1 . No informed consent . 2 . &lt; 18 year old . 3 . Previous know type 2 diabetes . 4 . Admission plasma glucose &gt; 12 mmol/L . 5 . Impaired renal function ( Screatinine ≥ 130 μmol/L need renal dialysis ) . 6 . BMI &gt; 30 . 7 . Known Type 1 diabetes , GAD positive Cpeptide &lt; 0.30 . 8 . Patients severe concomitant disease ( i.e . malignancy , liver failure ) . 9 . Patients discharge plan Coronary Artery Bypass Grafting percutaneous coronary intervention . 10 . Congestive heart failure ( NYHA IIIIV ) . 11 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception . 12 . Patients , opinion investigator , difficulty comply protocol ( example : alcohol drug abuse , psychiatric disorder , resident outside catchment area ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Type 2 diabetes , IGT , Myocardial infarction , Incretins</keyword>
</DOC>